Low-molecular-weight heparin overdose: Management by observation

Annals of Pharmacotherapy

Volumn 44, Issue 11, 2010, Pages 1836-1839

  Monte, Andrew A ^a,b   Bodmer, Michael ^a   Schaeffer, Tammi H ^a,b  

^a ROCKY MOUNTAIN POISON AND DRUG CENTER   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Dalteparin; Enoxaparin; LMWH overdose; LMWH reversal; Low molecular weight heparin; Protamine

Indexed keywords

AMLODIPINE; AMPHETAMINE; ARIPIPRAZOLE; BLOOD CLOTTING FACTOR 10A; CLONAZEPAM; CYCLOBENZAPRINE; DALTEPARIN; DEXAMPHETAMINE; DOCUSATE SODIUM; ENOXAPARIN; LABETALOL; LISINOPRIL; LOW MOLECULAR WEIGHT HEPARIN; MYCOPHENOLIC ACID; OMEPRAZOLE; OXYCODONE; PREDNISONE; PROTAMINE; RECOMBINANT BLOOD CLOTTING FACTOR 7A; TEMAZEPAM; VITAMIN D; WARFARIN;

ADULT; ALCOHOL INTOXICATION; ANTICOAGULANT THERAPY; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; BLEEDING; CASE REPORT; CHRONIC PAIN; DRUG OVERDOSE; FEMALE; HUMAN; KIDNEY FAILURE; LUNG EMBOLISM; MALE; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; SUICIDE ATTEMPT; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOEMBOLISM;

ADULT; ANTICOAGULANTS; DALTEPARIN; ENOXAPARIN; FACTOR XA; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; OVERDOSE; SUICIDE, ATTEMPTED;

EID: 78049460819     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1P318     Document Type: Article

References (26)

1. Harrington RA, Becker RC, Cannon CP, et al. Antithrombotic therapy for non-ST-segment elevation acute coronary syndromes: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008;133:670S-707S. DOI 10.1378/chest.08-0691
2. van Dongen CJ, van den Belt AG, Prins MH, Lensing AW. Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. Cochrane Database Syst Rev 2004:CD001100. DOI 10.1002/14651858.CD001100.pub2
3. Fareed J, Hoppensteadt D, Walenga J, et al. Pharmacodynamic and pharmacokinetic properties of enoxaparin: implications for clinical practice. Clin Pharmacokinet 2003;42:1043-57.
4. Hirsh J, Bauer KA, Donati MB, Gould M, Samama MM, Weitz JI. Parenteral anticoagulants: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008;133:141S-59S. DOI 10.1378/chest.08-0689
5. Product information. Fragmin (dalteparin). New York, NY: Pfizer Inc, March 2010.
6. Product information. Lovenox (enoxaparin). Bridgewater, NJ: Sanofi-Aventis US LLC, December 2009.
7. de Maistre E, Allart C, Lecompte T, Bollaert PE. Severe bleeding associated with use of low molecular weight heparin and selective serotonin reuptake inhibitors. Am J Med 2002;113:530-2.
8. Lindqvist PG, Dahlback B. Bleeding complications associated with low molecular weight heparin prophylaxis during pregnancy. Thromb Haemost 2000;84:140-1.
9. Crowther MA, Berry LR, Monagle PT, Chan AK. Mechanisms responsible for the failure of protamine to inactivate low-molecular-weight heparin. Br J Haematol 2002;116:178-86.
10. Chawla LS, Moore G, Seneff MG. Incomplete reversal of enoxaparin toxicity by protamine: implications of renal insufficiency, obesity, and low molecular weight heparin sulfate content. Obes Surg 2004;14:695-8. DOI 10.1381/096089204323093516
11. Wiernikowski JT, Chan A, Lo G. Reversal of anti-thrombin activity using protamine sulfate. Experience in a neonate with a 10-fold overdose of enoxaparin. Thromb Res 2007;120:303-5. DOI 10.1016/j.thromres.2006.08.011
12. Dietrich CP, Shinjo SK, Moraes FA, et al. Structural features and bleeding activity of commercial low molecular weight heparins: neutralization by ATP and protamine. Semin Thromb Hemost 1999;25(suppl 3):43-50.
13. Baumelou A, Singlas E, Petitclerc T, Desmichels D, Jacobs C, Soria J. Pharmacokinetics of a low molecular weight heparin (reviparine) in hemodialyzed patients. Nephron 1994;68:202-6.
14. Brophy DF, Wazny LD, Gehr TW, Comstock TJ, Venitz J. The pharmacokinetics of subcutaneous enoxaparin in end-stage renal disease. Pharmacotherapy 2001;21:169-74.
15. Guillet B, Simon N, Sampol JJ, et al. Pharmacokinetics of the low molecular weight heparin enoxaparin during 48 h after bolus administration as an anticoagulant in haemodialysis. Nephrol Dial Transplant 2003;18:2348-53.
16. Nutescu EA, Spinler SA, Wittkowsky A, Dager WE. Low-molecular-weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings. Ann Pharmacother 2009;43:1064-83. DOI 10.1345/aph.1L194
17. Schmid P, Fischer AG, Wuillemin WA. Low-molecular-weight heparin in patients with renal insufficiency. Swiss Med Wkly 2009;139:438-52.
18. Young G, Yonekawa KE, Nakagawa PA, Blain RC, Lovejoy AE, Nugent DJ. Recombinant activated factor VII effectively reverses the anticoagulant effects of heparin, enoxaparin, fondaparinux, argatroban, and bivalirudin ex vivo as measured using thromboelastography. Blood Coagul Fibrinolysis 2007;18:547-53. DOI 10.1097/MBC.0b013e328201c9a9
19. Bijsterveld NR, Moons AH, Boekholdt SM, et al. Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers. Circulation 2002;106:2550-4.
20. Bijsterveld NR, Vink R, van Aken BE, et al. Recombinant factor VIIa reverses the anticoagulant effect of the long-acting pentasaccharide idraparinux in healthy volunteers. Br J Haematol 2004;124:653-8.
21. Hu Q, Brady JO. Recombinant activated factor VII for treatment of enoxaparin-induced bleeding. Mayo Clin Proc 2004;79:827.
22. Ng HJ, Koh LP, Lee LH. Successful control of postsurgical bleeding by recombinant factor VIIa in a renal failure patient given low molecular weight heparin and aspirin. Ann Hematol 2003;82:257-8. DOI 10.1007/s00277-003-0633-1
23. Vavra KA, Lutz MF, Smythe MA. Recombinant factor VIIa to manage major bleeding from newer parenteral anticoagulants. Ann Pharmacother 2010;44:718-26. DOI 10.1345/aph.1M447
24. Wakefield TW, Andrews PC, Wrobleski SK, et al. A [+18RGD] protamine variant for nontoxic and effective reversal of conventional heparin and low-molecular-weight heparin anticoagulation. J Surg Res 1996;63:280-6. DOI 10.1006/jsre.1996.0261
25. Agnelli G, Iorio A, Renga C, et al. Prolonged antithrombin activity of low-molecular-weight heparins. Clinical implications for the treatment of thromboembolic diseases. Circulation 1995;92:2819-24.
26. Nybo M, Madsen JS. Serious anaphylactic reactions due to protamine sulfate: a systematic literature review. Basic Clin Pharmacol Toxicol 2008;103:192-6.